Welcome to our dedicated page for Hinge Health SEC filings (Ticker: HNGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Hinge Health, Inc. (NYSE: HNGE) SEC filings, giving investors and researchers a primary source for the company’s regulatory disclosures. As a public company in the healthcare and health information services space, Hinge Health uses its filings to report financial results, describe material events, and document key corporate actions.
Current and prospective shareholders can review periodic reports and current reports on Form 8-K that summarize important developments. Recent 8-K filings have covered topics such as quarterly financial results, the use of non-GAAP financial measures, and the authorization of a share repurchase program for the company’s Class A common stock. These filings often reference accompanying press releases that provide detailed financial statements, reconciliations of non-GAAP metrics, and information about earnings conference calls.
Other 8-K disclosures describe events related to the company’s initial public offering, including lock-up agreements that restrict the sale or transfer of shares for a defined period and the conditions under which certain shares become eligible for earlier release. Such filings help investors understand share supply dynamics, insider selling restrictions, and the timing of potential changes in the public float.
Through its SEC reports, Hinge Health also explains how it presents metrics like calculated billings and discusses the seasonality associated with client launches and platform access. These documents complement the company’s press releases about its AI-powered musculoskeletal care platform, wearable devices, and clinician-supported programs by providing audited or reviewed financial data and formal regulatory context.
On Stock Titan, SEC filings for HNGE are updated as they are posted to the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key figures, and surface important sections, such as discussions of results of operations, share repurchase details, and other material events disclosed in Hinge Health’s filings.
Hinge Health, Inc. President James Pursley reported a routine tax-related share disposition. On this Form 4, 831 shares of Class A Common Stock were withheld and cancelled at a value of $38.56 per share to cover federal and state tax withholding from the vesting of restricted stock units. After this transaction, Pursley directly holds 731,273 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. Chief Financial Officer James Budge reported a disposition of 4,614 shares of Class A Common Stock on a tax-withholding basis. The shares were relinquished to the company at $38.56 per share to cover federal and state tax obligations from vesting restricted stock units. Following this exempt transaction under Section 16b-3(e), Budge directly holds 396,813 shares of Class A Common Stock.
Hinge Health Inc disclosure: The Vanguard Group filed an amendment reporting 0 shares beneficially owned of Hinge Health common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, causing certain Vanguard subsidiaries to report separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The report states Vanguard and related investment vehicles retain the right to receive dividends or sale proceeds where applicable; no single other person holds >5% of the class according to the filing.
Hinge Health, Inc. Chief Financial Officer James Budge reported selling a total of 11,006 shares of Class A Common Stock on March 23, 2026 in three open-market transactions. The reported weighted average sale prices were $41.2858, $42.4514 and $42.8023 per share, each with specified intraday price ranges.
These sales were effected under a Rule 10b5-1 trading plan adopted by Budge on June 12, 2025, indicating they were pre-arranged. Following the transactions, he directly owns 401,427 shares of Hinge Health Class A Common Stock.
Hinge Health, Inc. president James Pursley sold 15,000 shares of Class A Common Stock in open-market transactions. The sales on March 23, 2026 were split into three trades: 2,256 shares at $41.2126, 9,838 shares at $42.3571, and 2,906 shares at $42.7538.
These trades were executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. After the transactions, Pursley directly owned 732,104 shares of Hinge Health Class A Common Stock.
HNGE affiliate reported a proposed sale of securities under a Form 144. The filing lists a 10b5-1 sale by James Budge of 14,763 shares on 02/23/2026 with gross proceeds of $580,736.79. The broker is listed as Morgan Stanley Smith Barney LLC.
James Pursley reported a sale of 15,000 common shares. The filing shows 15,000 shares sold under a 10b5-1 plan on 02/23/2026 for $589,983. The securities originated as Performance Stock Units granted 04/01/2023 and the broker listed is Morgan Stanley Smith Barney LLC. The notice was filed on 03/23/2026.
Sloat Tyler reported acquisition or exercise transactions in this Form 4 filing.
Hinge Health, Inc. director Tyler Sloat received an award of 9,896 shares of Class A Common Stock as a grant, reported at a price of $0.00 per share. After this transaction, he directly holds 9,896 shares.
The filing explains that these 9,896 shares are restricted stock units (RSUs), which vest in accordance with the terms of the award. Each RSU represents a contingent right to receive one share of Class A Common Stock, so the actual share delivery depends on future vesting conditions.
Hinge Health, Inc. director Tyler Sloat filed an initial ownership report on Form 3. This filing establishes his status as a director and discloses that there are no reportable transactions or derivative holdings included in this submission.
Hinge Health, Inc. has appointed Tyler Sloat to its Board of Directors as a Class I director, effective March 16, 2026. His term runs until the company’s 2026 annual stockholders’ meeting, and he will serve as Chair of the Compensation Committee and a member of the Audit Committee.
Sloat is currently Chief Operating Officer and Chief Financial Officer of Freshworks Inc. and previously served as CFO of Zuora Inc. He will receive standard non-employee director compensation, including an initial grant of RSUs valued at $400,000 vesting over three years, annual cash retainers for his board and committee roles, and eligibility for future annual RSU awards.